Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027, a report published by Ken Research gives a thorough analysis on the market opportunities for the therapeutics of binge eating disorder, and gives a forecast of the same to 2027. It discussed the current market landscape for BED therapeutics in the seven major markets: US, France, Germany, Italy, Spain, UK and Japan. Comparing the available options with each other, as well as across the global front; the report also talks about the required needs in the BED treatment and its management. The report contains insights on the drivers and barriers in the market.
First identified in 1959 by Albert Hunkard, Binge Eating Disorder is a condition wherein the subject consumes large amount of food at irregular intervals- often secretly. The condition which affects so many and is known to have a link to obesity, was surprisingly recognised as an official distinct disorder in as late as 2013. With the official recognition, the awareness about the disorder has been increasing. However, due to many reasons, an effective identification and diagnosis of the condition is on a low scale.
Classified along with conditions like anorexia nervosa and bulimia nervosa, binge eating disorder is the most common occurring eating disorder in USA. It generally occurs amongst the adolescents and adults. The concern around the disorder is not just the obesity but the root causes often associated with it. Experts understand that BED generally occurs alongside depression, anxiety disorder or substance abuse or even lifestyle stress. Hence, a proper diagnosis and treating the root cause becomes important in the treatment.
The problem faced by practitioners is identification of the disorder. In many cases binging behaviour is triggered only by comfort food that results in just a case of overeating that is not regular. The catch is to find a pattern not just in the eating habits but the behavioural aspects as well. In many cases of BED, patients are caught in a viscous cycle of disorders. There is an inability to understand whether it’s the depression that results into binge eating or the binge eating is making them depressed. This can sometimes lead to excessive diet or purging, again resulting into depression. Hence, a combined treatment that includes a psychiatrist, therapists and nutritionists is required.
Cognitive Behavioural Theory or CBT is regarded as the first in line treatment for BED. Another alternative treatment is Pharmacotherapy. But this line of treatment is still into development, with only one pharmacotherapy to have received approved label expansion from FDA. With increasing awareness about the disorder, more number of cases are coming to light. Researchers and practitioners are trying to develop new drugs and therapies to cure the same. With increased connectivity and access to information, patients from different countries have also started to look for the treatment options.
The companies covered in the concerned report are: Shire, Sunovion, Novo Nordisk, H. Lundbeck, Eli Lilly, Orexigen Therapeutics, Vivus, Jazz Pharmaceuticals
For more information, click on the link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/binge-eating-disorder/157370-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91 9015378249
